Approaches to measuring the effects of wake-promoting drugs: A focus on cognitive function

Human Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 371-389

  Edgar, Christopher J ^a   Pace Schott, Edward F ^b   Wesnes, Keith A ^a  

^a Harvard Medical School ^*  (United Kingdom)

^b Cognitive Drug Research Ltd ^*  (United States)

Author keywords

Cognition; Drug development; Sleep wake cycle; Wake promoting

Indexed keywords

AMPHETAMINE; ARMODAFINIL; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPLIVANSERIN; ESZOPICLONE; GUANFACINE; HYPNOTIC AGENT; MELATONIN; METHYLPHENIDATE; MODAFINIL; MUSCARINIC RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; OXYBATE SODIUM; PLACEBO; PRAMIPEXOLE; PRUVANSERIN; PSYCHOSTIMULANT AGENT; RAMELTEON; UNINDEXED DRUG; VOLINANSERIN; ZALEPLON; ZOLPIDEM; ZOPICLONE; CENTRAL STIMULANT AGENT;

ALERTNESS; AROUSAL; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; FATIGUE; HUMAN; INSOMNIA; MENTAL PERFORMANCE; NARCOLEPSY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; WAKEFULNESS; BRAIN; DRUG EFFECT; HISTOLOGY; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; QUESTIONNAIRE; SLEEP;

BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; SLEEP; WAKEFULNESS;

EID: 70149117700     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1034     Document Type: Review

References (221)

1. US Modafinil in Narcolepsy Multicenter Study Group. 1998. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 43: 88-97.
2. The National Sleep Foundation. 2005. Sleep in America Poll. National Sleep Foundation: USA.
3. Adelsberg BR. 1997. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 157: 494-500.
4. Aeschbach D, Postolache TT, Sher L, Matthews JR, Jackson MA, Wehr TA. 2001. Evidence from the waking electroencephalogram that short sleepers live under higher homeostatic sleep pressure than long sleepers. Neuroscience 102: 493-502.
5. Anderson KJ. 1994. Impulsitivity, caffeine, and task difficulty: a within-subjects test of the Yerkes-Dodson law. Pers Individ Dif 16: 813-829.
6. Aston-Jones G, Cohen JD. 2005. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28: 403-450.
7. Attwood AS, Higgs S, Terry P. 2007. Differential responsiveness to caffeine and perceived effects of caffeine in moderate and high regular caffeine consumers. Psychopharmacology (Berl) 190: 469-477.
8. Backhaus J, Junghanns K, Born J, Hohaus K, Faasch F, Hohagen F. 2006. Impaired declarative memory consolidation during sleep in patients with primary insomnia: influence of sleep architecture and nocturnal cortisol release. Biol Psychiatry 60: 1324-1330.
9. Balkin TJ, Braun AR,Wesensten NJ, et al. 2002. The process of awakening: a PET study of regional brain activity patterns mediating the re-establishment of alertness and consciousness. Brain 125: 2308-2319.
10. Banks S, Dinges DF. 2007. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 3: 519-528.
11. Barbier AJ, Berridge C, Dugovic C, et al. 2004. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143: 649-661.
12. Barbier AJ, Bradbury MJ. 2007. Histaminergic control of sleep-wake cycles: recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 6: 31-43.
13. Barker MJ, Greenwood KM, Jackson M, Crowe SF. 2004. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18: 37-48.
14. Barone JJ, Roberts HR. 1996. Caffeine consumption. Food Chem Toxicol 34: 119-129.
15. Bart Sangal R, Sangal JM, Thorp K. 2008. Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness. Sleep Med 9: 506-510.
16. Basheer R, Strecker RE, Thakkar MM, Mccarley RW. 2004. Adenosine and sleep-wake regulation. Prog Neurobiol 73: 379-396.
17. Bishop C, Roehrs T, Rosenthal L, Roth T. 1997. Alerting effects of methylphenidate under basal and sleep-deprived conditions. Exp Clin Psychopharmacol 5: 344-352.
18. Blandina P, Giorgetti M, Bartolini L, et al. 1996. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 119: 1656-1664.
19. Bonaventure P, Letavic M, Dugovic C, et al. 2007. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73: 1084-1096.
20. Bonnet MH, Arand DL. 2003. Clinical effects of sleep fragmentation versus sleep deprivation. Sleep Med Rev 7: 297-310.
21. Bonnet MH, Balkin TJ, Dinges DF, Roehrs T, Rogers NL, Wesensten NJ. 2005. The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and stimulant task force of the American academy of sleep medicine. Sleep 28: 1163-1187.
22. Bonnet MH, Webb WB. 1979. The return to sleep. Biol Psychol 8: 225-233.
23. Borbely AA. 1982. A two-process model of sleep regulation. Hum Neurobiol 1: 195-204.
24. Bruck D, Kennedy GA, Cooper A, Apel S. 2005. Diurnal actigraphy and stimulant efficacy in narcolepsy. Hum Psychopharmacol 20: 105-113.
25. Buckner RL, Andrews-Hanna JR, Schacter DL. 2008. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124: 1-38.
26. Buffett-Jerrott SE, Stewart SH. 2002. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8: 45-58.
27. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213.
28. Cajochen C, Brunner DP, Krauchi K, Graw P, Wirz-Justice A. 1995. Power density in theta/alpha frequencies of the waking EEG progressively increases during sustained wakefulness. Sleep 18: 890-894.
29. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. 1986. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 9: 519-524.
30. Carter AJ, O'connor WT, Carter MJ, Ungerstedt U. 1995. Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J Pharmacol Exp Ther 273: 637-642.
31. Carter LP, Richards BD, Mintzer MZ, Griffiths RR. 2006. Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31: 2537-2551.
32. Chamberlain SR, Muller U, Robbins TW, Sahakian BJ. 2006. Neuropharmacological modulation of cognition. Curr Opin Neurol 19: 607-612.
33. Chapotot F, Pigeau R, Canini F, Bourdon L, Buguet A. 2003. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology (Berl) 166: 127-138.
34. Chee MW, Chuah LY. 2008. Functional neuroimaging insights into how sleep and sleep deprivation affect memory and cognition. Curr Opin Neurol 21: 417-423.
35. Childs E, De Wit H. 2006. Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 185: 514-523.
36. Christopher G, Sutherland D, Smith A. 2005. Effects of caffeine in non-withdrawn volunteers. Hum Psychopharmacol 20: 47-53.
37. Chu NS. 2002. Neurological aspects of areca and betel chewing. Addict Biol 7: 111-114.
38. Chuah LY, Chee MW. 2008. Functional neuroimaging of sleep deprived healthy volunteers and persons with sleep disorders: a brief review. Ann Acad Med Singapore 37: 689-694.
39. Cohen AL, Jhung MA, Budnitz DS. 2006. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med 354: 2294-2295.
40. Colrain IM, Campbell KB. 2007. The use of evoked potentials in sleep research. Sleep Med Rev 11: 277-293.
41. Conrin J. 1980. The EEG effects of tobacco smoking - a review. Clin Electroencephalogr 11: 180-187.
42. Cooke JR, Ancoli-Israel S. 2006. Sleep and its disorders in older adults. Psychiatr Clin North Am 29: 1077-1093 (Abstract x-xi).
43. Cools R, Roberts AC, Robbins TW. 2008. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci 12: 31-40.
44. Court JA, Piggott MA, Lloyd S, et al. 2000. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 98: 79-87.
45. Crowley SJ, Acebo C, Carskadon MA. 2007. Sleep, circadian rhythms, and delayed phase in adolescence. Sleep Med 8: 602-612.
46. Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, Chouvet G. 2007. Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. Neuropsychopharmacology 32: 1232-1241.
47. Davila DG, Hurt RD, Offord KP, Harris CD, Shepard JW, Jr. 1994. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 150: 469-474.
48. Devine EB, Hakim Z, Green J. 2005. A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adults. Pharmacoeconomics 23: 889-912.
49. Dinges DF. 1990. Are you awake? Cognitive performance and reverie during the hypnopompic state. In Sleep and Cognition, Bootzin R, Kihlstrom J, Schacter DL (eds). American Psychological Association: Washington, DC.
50. Dinges DF, Powell JW. 1985. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Methods Instrum Comput 17: 652-655.
51. Doghramji K, Mitler MM, Sangal RB, et al. 1997. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol 103: 554-562.
52. Dorman T. 1992. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol 6 (Suppl 4): 53-58.
53. Drummond SP, Brown GG. 2001. The effects of total sleep deprivation on cerebral responses to cognitive performance. Neuropsychopharmacology 25: S68-73.
54. Dunbar G, Boeijinga PH, Demazieres A, et al. 2007a. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191: 919-929.
55. Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J. 2007b. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 21: 171-178.
56. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. 2004. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19: 305-322.
57. Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E. 1990. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 180: 49-58.
58. Ellis BW, Johns MW, Lancaster R, Raptopoulos P, Angelopoulos N, Priest RG. 1981. The St. Mary's Hospital sleep questionnaire: a study of reliability. Sleep 4: 93-97.
59. Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC. 1998. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 87: 905-911.
60. Erwin CW, Marsh GR. 1990. Ambulatory polysomnography in the study of patients with disorders of initiating and maintaining sleep. Semin Neurol 10: 123-130.
61. Etminan M, Samii A, Takkouche B, Rochon PA. 2001. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf 24: 863-868.
62. Everitt BJ, Robbins TW. 1997. Central cholinergic systems and cognition. Annu Rev Psychol 48: 649-684.
63. Farrow TF, Hunter MD, Haque R, Spence SA. 2006. Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial. Br J Psychiatry 189: 461-462.
64. Ferrara M, De Gennaro L. 2000. The sleep inertia phenomenon during the sleep-wake transition: theoretical and operational issues. Aviat Space Environ Med 71: 843-848.
65. Ferraro L, Tanganelli S, O'connor WT, Antonelli T, Rambert F, Fuxe K. 1996. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220: 5-8.
66. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. 1997. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20: 482-487.
67. Fisone G, Borgkvist A, Usiello A. 2004. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61: 857-872.
68. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
69. Friedman JH, Brown RG, Comella C, et al. 2007. Fatigue in Parkinson's disease: a review. Mov Disord 22: 297-308.
70. Gilbert DG, Dibb WD, Plath LC, Hiyane SG. 2000. Effects of nicotine and caffeine, separately and in combination, on EEG topography, mood, heart rate, cortisol, and vigilance. Psychophysiology 37: 583-595.
71. Gillberg M, Kecklund G, Akerstedt T. 1994. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep 17: 236-241.
72. Gillin JC, Lardon M, Ruiz C, Golshan S, Salin-Pascual R. 1994. Dose-dependent effects of transdermal nicotine on early morning awakening and rapid eye movement sleep time in nonsmoking normal volunteers. J Clin Psychopharmacol 14: 264-267.
73. Giovannini MG, Bartolini L, Bacciottini L, Greco L, Blandina P. 1999. Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav Brain Res 104: 147-155.
74. Greneche J, Krieger J, Erhardt C, et al. 2008. EEG spectral power and sleepiness during 24 h of sustained wakefulness in patients with obstructive sleep apnea syndrome. Clin Neurophysiol 119: 418-428.
75. Griesar WS, Zajdel DP, Oken BS. 2002. Nicotine effects on alertness and spatial attention in non-smokers. Nicotine Tob Res 4: 185-194.
76. Guilleminault C, Brooks SN. 2001. Excessive daytime sleepiness: a challenge for the practising neurologist. Brain 124: 1482-1491.
77. Gyllenhaal C, Merritt SL, Peterson SD, Block KI, Gochenour T. 2000. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev 4: 229-251.
78. Hahn B, Ross TJ, Yang Y, Kim I, Huestis MA, Stein EA. 2007. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci 27: 3477-3489.
79. Harrison Y, Horne JA. 2000. The impact of sleep deprivation on decision making: a review. J Exp Psychol Appl 6: 236-249.
80. Harrison J, Wesnes K. 2006. Objective cognitive testing and patient reported accounts of cognitive function. PRO Newsl 36: 5-8.
81. Harsh JR, Hayduk R, Rosenberg R, et al. 2006. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22: 761-774.
82. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. 2005. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 179: 813-825.
83. Henningfield JE, Miyasato K, Jasinski DR. 1985. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234: 1-12.
84. Hewlett P, Smith A. 2007. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. Hum Psychopharmacol 22: 339-350.
85. Hillyard SA, Kutas M. 2002. Event-related potentials and magnetic fields in the human brain. In Neuropsychopharmacology: The Fifth Generation of Progress, Charney D, Coyle J, Davis K, Nemeroff C (eds). Lippincott Williams and Wilkins: Philadelphia, PA.
86. Hindmarch I, Gudgeon AC. 1980. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol 10: 145-150.
87. Hindmarch I, Rigney U, Stanley N, Quinlan P, Rycroft J, Lane J. 2000. A naturalistic investigation of the effects of day-long consumption of tea, coffee and water on alertness, sleep onset and sleep quality. Psychopharmacology (Berl) 149: 203-216.
88. Hirshkowitz M, Black J. 2007. Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study. CNS Drugs 21: 407-416.
89. Hirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S, Roth T. 2007. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 101: 616-627.
90. Hobson JA, Pace-Schott EF, Stickgold R. 2000. Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav Brain Sci 23: 793-842.
91. Hoddes E, Dement W, Zarcone V. 1972. The development and use of the Stanford sleepiness scale. Psychophysiology 9: 150.
92. Hofer-Tinguely G, Achermann P, Landolt HP, et al. 2005. Sleep inertia: performance changes after sleep, rest and active waking. Brain Res Cogn Brain Res 22: 323-331.
93. Hogervorst E, Riedel WJ, Kovacs E, Brouns F, Jolles J. 1999. Caffeine improves cognitive performance after strenuous physical exercise. Int J Sports Med 20: 354-361.
94. Honma H, Kohsaka M, Fukuda N, Kobayashi R, Sakakibara S, Koyama T. 2000. Differences in electroencephalogram power densities between genuine narcolepsy and secondary narcolepsy. Psychiatry Clin Neurosci 54: 326-327.
95. Huang ZL, Qu WM, Eguchi N, et al. 2005. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 8: 858-859.
96. Huang ZL, Urade Y, Hayaishi O. 2007. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 7: 33-38.
97. Jean-Louis G, Von Gizycki H, Zizi F, Spielman A, Hauri P, Taub H. 1997. The actigraph data analysis software: II. A novel approach to scoring and interpreting sleep-wake activity. Percept Mot Skills 85: 219-226.
98. Johns MW. 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-545.
99. Johns MW. 1992. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 15: 376-381.
100. Jones BE. 2005. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci 26: 578-586.
101. Joseph KC, Sitaram N. 1990. Topographical sleep EEG response to arecoline. Psychiatry Res 35: 91-94.
102. Kaasinen V, Rinne JO. 2002. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev 26: 785-793.
103. Karila L, Gorelick D, Weinstein A, et al. 2008. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11: 425-438.
104. Kim H, Dinges DF, Young T. 2007. Sleep-disordered breathing and psychomotor vigilance in a community-based sample. Sleep 30: 1309-1316.
105. Kitagawa H, Takenouchi T, Azuma R, et al. 2003. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
106. Kiyashchenko LI, Mileykovskiy BY, Maidment N, et al. 2002. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 22: 5282-5286.
107. Kloss JD, Szuba MP, Dinges DF. 2002. Sleep loss and sleepiness: physiological and neurobehavioural effects. In American College of Neuropsychopharmacology, Fifth Generation of Progress, Charney D, Coyle J, Davis K, Nemeroff C (eds). Lippincott, Williams and Wilkins: New York.
108. Komater VA, Browman KE, Curzon P, Hancock AA, Decker MW, Fox GB. 2003. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) 167: 363-372.
109. Komater VA, Buckley MJ, Browman KE, et al. 2005. Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav Brain Res 159: 295-300.
110. Kroner S, Schall U, Ward PB, et al. 1999. Effects of prepulses and damphetamine on performance and event-related potential measures on an auditory discrimination task. Psychopharmacology (Berl) 145: 123-132.
111. Kuenzel HE, Murck H, Held K, Ziegenbein M, Steiger A. 2004. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. Pharmacopsychiatry 37: 193-195.
112. Lagarde D, Batejat D, Van Beers P, Sarafian D, Pradella S. 1995. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol 9: 271-279.
113. Landolt HP. 2008. Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol 75: 2070-2079.
114. Landolt HP, Retey JV, Tonz K, et al. 2004. Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans. Neuropsychopharmacology 29: 1933-1939.
115. Lena I, Parrot S, Deschaux O, et al. 2005. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J Neurosci Res 81: 891-899.
116. Lieberman HR, Wurtman RJ, Emde GG, Coviella IL. 1987. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 7: 315-320.
117. Lim J, Dinges DF. 2008. Sleep deprivation and vigilant attention. Ann N Y Acad Sci 1129: 305-322.
118. Loke WH. 1988. Effects of caffeine on mood and memory. Physiol Behav 44: 367-372.
119. Lopez J, Lopez V, Rojas D, et al. 2004. Effect of psychostimulants on distinct attentional parameters in attentional deficit/hyperactivity disorder. Biol Res 37: 461-468.
120. Lu J, Sherman D, Devor M, Saper CB. 2006. A putative flip-flop switch for control of REM sleep. Nature 441: 589-594.
121. Luppi PH, Gervasoni D, Verret L, et al. 2006. Paradoxical (REM) sleep genesis: the switch from an aminergic-cholinergic to a GABAergicglutamatergic hypothesis. J Physiol Paris 100: 271-283.
122. Mackworth JF. 1965. The effect of amphetamine on the detectability of signals in a vigilance task. Can J Psychol 19: 104-110.
123. Mackworth NH. 1961. Researches on the measurement of human performance. In Selected Papers on Human Fact, Sinaiko HW (ed.). His Majesty's Stationery Office: London.
124. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. 2007. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol 15: 123-133.
125. Mansvelder HD, Van Aerde KI, Couey JJ, Brussaard AB. 2006. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl) 184: 292-305.
126. Martin WR, Sloan JW, Sapira JD, Jasinski DR. 1971. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
127. Mathieu A, Mazza S, Petit D, et al. 2007. Does age worsen EEG slowing and attention deficits in obstructive sleep apnea syndrome? Clin Neurophysiol 118: 1538-1544.
128. Maubach K. 2003. GABA(A) receptor subtype selective cognition enhancers. Curr Drug Targets CNS Neurol Disord 2: 233-239.
129. Mehta MA, Riedel WJ. 2006. Dopaminergic enhancement of cognitive function. Curr Pharm Des 12: 2487-2500.
130. Meneses A. 1999. 5-HT system and cognition. Neurosci Biobehav Rev 23: 1111-1125.
131. Merica H, Fortune RD. 2004. State transitions between wake and sleep, and within the ultradian cycle, with focus on the link to neuronal activity. Sleep Med Rev 8: 473-485.
132. Mignot E, Nishino S. 2005. Emerging therapies in narcolepsy-cataplexy. Sleep 28: 754-763.
133. Minzenberg MJ, Carter CS. 2007. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477-1502.
134. Miyazaki S, Uchida S, Mukai J, Nishihara K. 2004. Clonidine effects on allnight human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. Psychiatry Clin Neurosci 58: 138-144.
135. Monk TH, Reynolds CF, Kupfer DJ, et al. 1994. The Pittsburgh Sleep Diary. J Sleep Res 3: 111-120.
136. Monti JM, Jantos H. 2008. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 172: 625-646.
137. Monti JM, Monti D. 2007. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 11: 113-133.
138. Muller U, Czymmek J, Thone-Otto A, Von Cramon DY. 2006. Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. Brain Inj 20: 157-160.
139. Murillo-Rodriguez E, Haro R, Palomero-Rivero M, Millan-Aldaco D, Drucker-Colin R. 2007. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 176: 353-357.
140. Muzur A, Pace-Schott EF, Hobson JA. 2002. The prefrontal cortex in sleep. Trends Cogn Sci 6: 475-481.
141. Newhouse PA, Belenky G, Thomas M, Thorne D, Sing HC, Fertig J. 1989. The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacology 2: 153-164.
142. Nieoullon A. 2002. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67: 53-83.
143. Nofzinger EA, Keshavan M. 2002. Sleep disturbances associated with neuropsychiatric disease. In American College of Neuropsychopharmacology, Fifth Generation of Progress, Charney D, Coyle J, Davis K, Nemeroff C (eds). Lippincott, Williams and Wilkins: New York.
144. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. 2000. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 42: 69-6981.
145. O'Brien CP, Dackis CA, Kampman K. 2006. Does modafinil produce euphoria? Am J Psychiatry 163: 1109.
146. Ochoa EL, Lasalde-Dominicci J. 2007. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol 27: 609-639.
147. Pace-Schott EF. 2007. The frontal lobes and dreaming. In The New Science of Dreaming, Barrett D, Mcnamara P (eds). Praeger, Greenwood Press: Westport, CT.
148. Pace-Schott EF, Hobson JA. 2002a. Basic mechanisms of sleep: new evidence on the neuroanatomy and neuromodulation of the NREM-REM cycle. In American College of Neuropsychopharmacology, Fifth Generation of Progress, Charney D, Coyle J, Davis K, Nemeroff C (eds). Lippincott, Williams and Wilkins: New York.
149. Pace-Schott EF, Hobson JA. 2002b. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3: 591-605.
150. Pace-Schott EF, Stickgold R, Muzur A, et al. 2005. Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. Am J Drug Alcohol Abuse 31: 571-591.
151. Paganini-Hill A, Kawas CH, Corrada MM. 2007. Non-alcoholic beverage and caffeine consumption and mortality: the Leisure World Cohort Study. Prev Med 44: 305-310.
152. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. 2007. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21: 995-1018.
153. Parmentier R, Anaclet C, Guhennec C, et al. 2007. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 73: 1157-1171.
154. Parrott AC, Hindmarch I. 1980. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) 71: 173-179.
155. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P. 2004. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25: 618-625.
156. Perry EK, Perry RH. 2004. Neurochemistry of consciousness: cholinergic pathologies in the human brain. Prog Brain Res 145: 287-299.
157. Physicians RCO. 2000. Nicotine addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians: London, United Kingdom.
158. Prosise GL, Bonnet MH, Berry RB, Dickel MJ. 1994. Effects of abstinence from smoking on sleep and daytime sleepiness. Chest 105: 1136-1141.
159. Ramos BP, Arnsten AF. 2007. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113: 523-536.
160. Retey JV, Adam M, Gottselig JM, et al. 2006. Adenosinergic mechanisms contribute to individual differences in sleep deprivation-induced changes in neurobehavioral function and brain rhythmic activity. J Neurosci 26: 10472-10479.
161. Rezvani AH, Levin ED. 2001. Cognitive effects of nicotine. Biol Psychiatry 49: 258-267.
162. Riedel W, Hogervorst E, Leboux R, Verhey F, Van Praag H, Jolles J. 1995. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 122: 158-168.
163. Robbins TW. 2005. Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol 493: 140-146.
164. Roehrs T, Turner L, Roth T. 2000. Effects of sleep loss on waking actigraphy. Sleep 23: 793-797.
165. Rosenthal L, Roehrs T, Zwyghuizen-Doorenbos A, Plath D, Roth T. 1991. Alerting effects of caffeine after normal and restricted sleep. Neuropsy- chopharmacology 4: 103-108.
166. Roth T, White D, Schmidt-Nowara W, et al. 2006. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 28: 689-706.
167. Rush CR, Kelly TH, Hays LR, Wooten AF. 2002. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 67: 311-322.
168. Sadeh A, Sharkey KM, Carskadon MA. 1994. Activity-based sleep-wake identification: an empirical test of methodological issues. Sleep 17: 201-207.
169. Sakurai T. 2007. Regulatory mechanism of sleep/wakefulness states by orexin. Tanpakushitsu Kakusan Koso 52: 1840-1848.
170. Saletu MT, Anderer P, Saletu-Zyhlarz GM, et al. 2005. EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil. Eur Arch Psychiatry Clin Neurosci 255: 20-32.
171. Saper CB, Chou TC, Scammell TE. 2001. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726-731.
172. Saper CB, Lu J, Chou TC, Gooley J. 2005a. The hypothalamic integrator for circadian rhythms. Trends Neurosci 28: 152-157.
173. Saper CB, Scammell TE, Lu J. 2005b. Hypothalamic regulation of sleep and circadian rhythms. Nature 437: 1257-1263.
174. Sarter M, Bruno JP. 2000. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 95: 933-952.
175. Sateia MJ, Kirby-Long P, Taylor JL. 2008. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Rev 12: 319-332.
176. Scheer FA, Shea TJ, Hilton MF, Shea SA. 2008. An endogenous circadian rhythm in sleep inertia results in greatest cognitive impairment upon awakening during the biological night. J Biol Rhythms 23: 353-361.
177. Schmidt C, Collette F, Cajochen C, Peigneux P. 2007. A time to think: circadian rhythms in human cognition. Cogn Neuropsychol 24: 755-789.
178. Schmitt JA, Hogervorst E, Vuurman EF, Jolles J, Riedel WJ. 2003. Memory functions and focussed attention in middle-aged and elderly subjects are unaffected by a low, acute dose of caffeine. J Nutr Health Aging 7: 301-303.
179. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. 2006. Serotonin and human cognitive performance. Curr Pharm Des 12: 2473-2486.
180. Schuh LM, Schuster CR, Hopper JA, Mendel CM. 2000. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 147: 339-346.
181. Schwartz JR. 2004. Pharmacologic management of daytime sleepiness. J Clin Psychiatry 65 (Suppl 16): 46-49.
182. Sechter D, Troy S, Paternetti S, Boyer P. 1999. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14: 41-48.
183. Shamsi Z, Hindmarch I. 2000. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 15: S3-S30.
184. Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ. 1994. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 33: 467-471.
185. Shekhar A, Potter WZ, Lightfoot J, et al. 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033-1039.
186. Siever LJ, Koenigsberg HW, Harvey P, et al. 2002. Cognitive and brain function in schizotypal personality disorder. Schizophr Res 54: 157-167.
187. Silvestri AJ, Sanford LD, Ross RJ, Mann GL, Pavlock A, Morrison AR. 2002. The central nucleus of the amygdala and the wake-promoting effects of modafinil. Brain Res 941: 43-52.
188. Slattum PW, Venitz J, Barr WH. 1996. Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers. J Clin Pharmacol 36: 1039-1050.
189. Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G. 2006. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 7: 147-154.
190. Steriade M. 2000. Corticothalamic resonance, states of vigilance and mentation. Neuroscience 101: 243-276.
191. Steriade M. 2004. Acetylcholine systems and rhythmic activities during the waking-sleep cycle. Prog Brain Res 145: 179-196.
192. Steriade M. 2006. Grouping of brain rhythms in corticothalamic systems. Neuroscience 137: 1087-1106.
193. Stickgold R, Walker MP. 2007. Sleep-dependent memory consolidation and reconsolidation. Sleep Med 8: 331-343.
194. Storm WF, Eddy DR, Welch CB, Hickey PA, Fischer J, Cardenas R. 2007. Cognitive performance following premature awakening from zolpidem or melatonin induced daytime sleep. Aviat Space Environ Med 78: 10-20.
195. Strecker RE, Morairty S, Thakkar MM, et al. 2000. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav Brain Res 115: 183-204.
196. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C. 1992. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 345: 461-465.
197. Tassi P, Muzet A. 2000. Sleep inertia. Sleep Med Rev 4: 341-353.
198. Theunissen EL, Vermeeren A, Vuurman EF, Ramaekers JG. 2006. Stimulating effects of H1-antagonists. Curr Pharm Des 12: 2501-2509.
199. Thiel CM. 2003. Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 80: 234-244.
200. Thomas RJ. 2005. Fatigue in the executive cortical network demonstrated in narcoleptics using functional magnetic resonance imaging-a preliminary study. Sleep Med 6: 399-406.
201. Thomas RJ, Kwong K. 2006. Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep 29: 1471-1481.
202. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. 2004a. Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder. Biol Psychiatry 55: 1031-1040.
203. Turner DC, Clark L, Pomarol-Clotet E, Mckenna P, Robbins TW, Sahakian BJ. 2004b. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29: 1363-1373.
204. Turner TH, Drummond SP, Salamat JS, Brown GG. 2007. Effects of 42 hr of total sleep deprivation on component processes of verbal working memory. Neuropsychology 21: 787-795.
205. Van Dongen HP, Price NJ, Mullington JM, Szuba MP, Kapoor SC, Dinges DF. 2001. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep 24: 813-819.
206. Vellas B, Cunha L, Gertz HJ, et al. 2005. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin 21: 1423-1429.
207. Vermeeren A. 2004. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18: 297-328.
208. Vermeeren A, Ramaekers JG, Vurman EFPM, Riedel W. 2006. Effects of histamine-3 receptor antagonism on electrocortical arousal during vigilance performance in man. Summer Meeting of The British Association for Psychopharmacology. Journal of Psychopharmacology: Oxford.
209. Walker MP, Stickgold R. 2006. Sleep, memory, and plasticity. Annu Rev Psychol 57: 139-166.
210. Watson CJ, Soto-Calderon H, Lydic R, Baghdoyan HA. 2008. Pontine reticular formation (PnO) administration of hypocretin-1 increases PnO GABA levels and wakefulness. Sleep 31: 453-464.
211. Watters PA, Martin F, Schreter Z. 1997. Caffeine and cognitive performance: the nonlinear Yerkes-Dodson Law. Hum Psychopharmacol 12: 247-249.
212. Wertz AT, Ronda JM, Czeisler CA, Wright KP, Jr. 2006. Effects of sleep inertia on cognition. JAMA 295: 163-164.
213. Wesensten NJ, Killgore WD, Balkin TJ. 2005. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 14: 255-266.
214. Wilens TE, Decker MW. 2007. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition. Biochem Pharmacol 74: 1212-1223.
215. Willner P, Scheel-Kruger J. 1991. The Mesolimbic Dopamine System: From Motivation to Action. Wiley: New York.
216. Wingen M, Kuypers KP, Ramaekers JG. 2007. The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers. Psychopharmacology (Berl) 190: 391-400.
217. Wisor JP, Eriksson KS. 2005. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 132: 1027-1034.
218. Witkin JM, Nelson DL. 2004. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103: 1-20.
219. Xi MC, Morales FR, Chase MH. 1999. Evidence that wakefulness and REM sleep are controlled by a GABAergic pontine mechanism. J Neurophysiol 82: 2015-2019.
220. Zahn TP, Rapoport JL. 1987. Autonomic nervous system effects of acute doses of caffeine in caffeine users and abstainers. Int J Psychophysiol 5: 33-41.
221. Zwyghuizen-Doorenbos A, Roehrs TA, Lipschutz L, Timms V, Roth T. 1990. Effects of caffeine on alertness. Psychopharmacology (Berl) 100: 36-39.